Pain Treatment After TKA With LIA and Intra-articular Continuous Infusion Pump

Sponsor
Region Skane (Other)
Overall Status
Completed
CT.gov ID
NCT01726686
Collaborator
(none)
200
1
2
49.9
4

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the effect on postoperative pain and function by adding intraarticular continuous infusion pump with local anesthetic after total knee arthroplasty where local infiltration analgesia has already been given.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

200 patients with osteoarthritis (OA) of the knee necessitating total knee arthroplasty are entered into the study. All patients are given a standard protocol of analgesics pre- and postoperatively. All patients get periarticular LIA-injection (150 ml) with a total of 300 mg Ropivacaine, 30 mg Toradol and 0.5 mg Adrenalin. In the end of the operation all patients get an epidural type of catheter intraarticular with a coupled continuous infusion pump that delivers 2 ml per hour and are disconnected after 48 hours. The University hospital pharmacy has prepared 200 pumps; 100 Active substance pumps with 100 ml Ropivacaine (10mg/ml) and 100 placebo pumps with 100 ml sodium chloride (NaCl). All patients are by computer software randomized to receive either active or placebo pump. Only one nurse, not involved in neither the operation nor the after treatment, has the key to what substance it is in the numbered pumps. Thus, it is a double blinded trial during the whole follow up period. Before the operation the patients are asked to fill out a knee specific outcome questionnaire, the Knee injury and Osteoarthritis Outcome Score (KOOS), and a general outcome questionnaire, the Euroqol (EQ-5D), and the knee range of motion is measured by a physiotherapist. After the operation the patients are monitored at the ward by the nurses and physiotherapists. The level of pain is measured twice daily (noon and 8 PM) according to the Visual-Analog-Scale (VAS). The range of motion and is measured on day 4 and at the day 14 and day 30 follow up. The number of days the patients need to stay in hospital after operation are registered. The amount of extra doses of analgesics the patient requires are registered as well as the complications (illness, wound problems, infections etc). The patients are to be followed clinically for 2 years as well as with outcome questionnaires.

Study Design

Study Type:
Interventional
Actual Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Evaluation of Intra-articular Continuous Infusion Pump With Ropivacaine in Addition to Local Infiltration Analgesia (LIA) in Total Knee Arthroplasty (TKA). A Placebo Controlled Randomised Trial.
Study Start Date :
Feb 1, 2010
Actual Primary Completion Date :
Jul 1, 2011
Actual Study Completion Date :
Apr 1, 2014

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Ropivacaine in the pump

The intra-articular Continuous Infusion Pump is filled with Ropivacaine,10 mg/ml, set at 2 ml/hour for 48 hours postoperatively.

Drug: Ropivacaine
100 ml Ropivacaine 10mg/ml in a continuous infusion pump set at 2 ml/hour
Other Names:
  • Naropin, Narop
  • Placebo Comparator: Placebo in the pump

    The intra-articular Continuous Infusion Pump is filled with NaCl, set at 2 ml/hour for 48 hours postoperatively.

    Drug: Placebo

    Outcome Measures

    Primary Outcome Measures

    1. Change in postoperative pain [The first 4 postoperative days at noon and 8 PM]

      The patient are asked to grade their pain on a VAS-scale (0-100)twice daily for the first 4 days after the TKA operation and at the 2 weeks follow-up. Changes in pain during this time frame are recorded to see if there are any differences between the two groups.

    Secondary Outcome Measures

    1. Extra oral analgesia consumption [First 4 postoperative days]

      All extra analgesia consumption are noted during the first 4 postoperative days. All patients have a standard pain management medication (depending on weight, age and sex) and only extra doses are noted.

    Other Outcome Measures

    1. Number of postoperative days in hospital [Duration of hospital stay, an expected time frame of 4-5 days]

      The number of days the patient needs to stay in hospital after operation are noted

    2. Pre- and postoperative knee range of motion [At preoperative admission for operation (about 2 weeks prior), day 4, 14 and 30 postoperatively]

      The range of motion in the affected knee are registered with a goniometer at the preoperative admission for operation, about 2 weeks prior to the operation and then on day 4, 14 and 30 postoperatively.

    3. Postoperative complications [2 years postoperatively]

      All complications postoperatively are registered for the first 2 years.

    4. Knee specific and general questionaire [preoperatively (about 2 weeks prior to op), 1 and 2 years postoperatively]

      The patients are asked to fill out the general health questionaire EQ-5D as well as the knee specific questionaire KOOS preoperatively at the admission for surgery (about 2 weeks before the operation) and at 1 and 2 year follow up.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Primary osteoarthritis of the knee necessitating total knee replacement

    • Patients who understand the conditions of the study and are willing to participate for the length of the prescribed follow-up

    Exclusion Criteria:
    • Known allergy to local anaesthetics or other contraindication for the use of local anaesthetics.

    • Treatment with Warfarin.

    • Bilateral operation

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Department of Orthopedics, Skane University Hospital, Lund University Lund Sweden

    Sponsors and Collaborators

    • Region Skane

    Investigators

    • Principal Investigator: Gunnar Flivik, MD PhD, Dept of Orthopedics, Skane University Hospital, Lund University, Sweden

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Gunnar Flivik, Associate Professor, MD PhD, Region Skane
    ClinicalTrials.gov Identifier:
    NCT01726686
    Other Study ID Numbers:
    • LIA-Pump_AA
    First Posted:
    Nov 15, 2012
    Last Update Posted:
    Nov 26, 2014
    Last Verified:
    Nov 1, 2014
    Keywords provided by Gunnar Flivik, Associate Professor, MD PhD, Region Skane
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 26, 2014